Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer

Detalhes bibliográficos
Autor(a) principal: Cardoso, HJ
Data de Publicação: 2015
Outros Autores: Vaz, CV, Correia, Sara, Figueira, Marília I, Marques, Ricardo, Baptista, Cláudio, Socorro, Sílvia
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.6/7665
Resumo: Imatinib mesylate is a chemotherapeutic drug that inhibits the tyrosine kinase activity of c-KIT and has been successfully used to treat leukemias and some solid tumors. However, its application for treatment of hormone-refractory prostate cancer (HRPC) has shown modest effectiveness and did not follow the outcomes in cultured cells or animal models. Moreover, the molecular pathways by which imatinib induces cytotoxicity in prostate cancer cells are poorly characterized.
id RCAP_c6e3d44fdd51897b252849f6e37d1b1c
oai_identifier_str oai:ubibliorum.ubi.pt:10400.6/7665
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancerc-KITDU14Hormone-refractory prostate cancerImatinibPC3Prostate cancer cellsImatinib mesylate is a chemotherapeutic drug that inhibits the tyrosine kinase activity of c-KIT and has been successfully used to treat leukemias and some solid tumors. However, its application for treatment of hormone-refractory prostate cancer (HRPC) has shown modest effectiveness and did not follow the outcomes in cultured cells or animal models. Moreover, the molecular pathways by which imatinib induces cytotoxicity in prostate cancer cells are poorly characterized.uBibliorumCardoso, HJVaz, CVCorreia, SaraFigueira, Marília IMarques, RicardoBaptista, CláudioSocorro, Sílvia2019-12-04T17:18:18Z2015-06-152015-06-15T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.6/7665eng10.1002/pros.22976metadata only accessinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-15T09:47:12Zoai:ubibliorum.ubi.pt:10400.6/7665Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:48:08.027026Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer
title Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer
spellingShingle Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer
Cardoso, HJ
c-KIT
DU14
Hormone-refractory prostate cancer
Imatinib
PC3
Prostate cancer cells
title_short Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer
title_full Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer
title_fullStr Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer
title_full_unstemmed Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer
title_sort Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer
author Cardoso, HJ
author_facet Cardoso, HJ
Vaz, CV
Correia, Sara
Figueira, Marília I
Marques, Ricardo
Baptista, Cláudio
Socorro, Sílvia
author_role author
author2 Vaz, CV
Correia, Sara
Figueira, Marília I
Marques, Ricardo
Baptista, Cláudio
Socorro, Sílvia
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv uBibliorum
dc.contributor.author.fl_str_mv Cardoso, HJ
Vaz, CV
Correia, Sara
Figueira, Marília I
Marques, Ricardo
Baptista, Cláudio
Socorro, Sílvia
dc.subject.por.fl_str_mv c-KIT
DU14
Hormone-refractory prostate cancer
Imatinib
PC3
Prostate cancer cells
topic c-KIT
DU14
Hormone-refractory prostate cancer
Imatinib
PC3
Prostate cancer cells
description Imatinib mesylate is a chemotherapeutic drug that inhibits the tyrosine kinase activity of c-KIT and has been successfully used to treat leukemias and some solid tumors. However, its application for treatment of hormone-refractory prostate cancer (HRPC) has shown modest effectiveness and did not follow the outcomes in cultured cells or animal models. Moreover, the molecular pathways by which imatinib induces cytotoxicity in prostate cancer cells are poorly characterized.
publishDate 2015
dc.date.none.fl_str_mv 2015-06-15
2015-06-15T00:00:00Z
2019-12-04T17:18:18Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.6/7665
url http://hdl.handle.net/10400.6/7665
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1002/pros.22976
dc.rights.driver.fl_str_mv metadata only access
info:eu-repo/semantics/openAccess
rights_invalid_str_mv metadata only access
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136376054087680

Registros relacionados